Priwitzerova Monika, Nie Guangjun, Sheftel Alex D, Pospisilova Dagmar, Divoky Vladimir, Ponka Prem
Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
Blood. 2005 Dec 1;106(12):3985-7. doi: 10.1182/blood-2005-04-1550. Epub 2005 Aug 9.
We have previously described a case of severe hypochromic microcytic anemia caused by a homozygous mutation in the divalent metal transporter 1 (DMT1 1285G > C). This mutation encodes for an amino acid substitution (E399D) and causes preferential skipping of exon 12 during processing of the DMT1 mRNA. To examine the functional consequences of this mutation, full-length DMT1 transcript with the patient's point mutation or a DMT1 transcript with exon 12 deleted was expressed in Chinese hamster ovary (CHO) cells. Our results demonstrate that the E399D substitution has no effect on protein expression and function. In contrast, deletion of exon 12 led to a decreased expression of the protein and disruption of its subcellular localization and iron uptake activity. We hypothesize that the residual protein in hematopoietic cells represents the functional E399D DMT1 variant, but because of its quantitative reduction, the iron uptake activity of DMT1 in the patient's erythroid cells is severely suppressed.
我们之前描述过一例由二价金属转运蛋白1(DMT1 1285G > C)纯合突变引起的严重低色素小细胞贫血病例。该突变编码一个氨基酸替换(E399D),并导致DMT1 mRNA加工过程中外显子12的优先跳跃。为了研究该突变的功能后果,将带有患者点突变的全长DMT1转录本或缺失外显子12的DMT1转录本在中国仓鼠卵巢(CHO)细胞中进行表达。我们的结果表明,E399D替换对蛋白质表达和功能没有影响。相比之下,外显子12的缺失导致蛋白质表达减少及其亚细胞定位和铁摄取活性的破坏。我们推测造血细胞中的残余蛋白代表功能性E399D DMT1变体,但由于其数量减少,患者红细胞中DMT1的铁摄取活性受到严重抑制。